Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
NCT06366451Phase 1Completed
- Sponsor
- Presage Biosciences
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilvegostomig, volrustomig, sabestomig and tilatamig samrotecan in head and neck squamous cell carcinoma (HNSCC), sponsored by Presage Biosciences. Primary endpoint: Evaluation of signature scores using Gene Set Variability Analysis. Started May 2024; status: completed.
02
Drugs
rilvegostomigvolrustomigsabestomigtilatamig samrotecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06366451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366451.